Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes

O’Sullivan, John F. ; Morningstar, Jordan E. ; Yang, Qiong ; Zheng, Baohui ; Gao, Yan ; Jeanfavre, Sarah ; Scott, Justin ; Fernandez, Celine LU ; Zheng, Hui and O’Connor, Sean , et al. (2017) In Journal of Clinical Investigation 127(12). p.4394-4402
Abstract

Unbiased, “nontargeted” metabolite profiling techniques hold considerable promise for biomarker and pathway discovery, in spite of the lack of successful applications to human disease. By integrating nontargeted metabolomics, genetics, and detailed human phenotyping, we identified dimethylguanidino valeric acid (DMGV) as an independent biomarker of CT-defined nonalcoholic fatty liver disease (NAFLD) in the offspring cohort of the Framingham Heart Study (FHS) participants. We verified the relationship between DMGV and early hepatic pathology. Specifically, plasma DMGV levels were correlated with biopsy-proven nonalcoholic steatohepatitis (NASH) in a hospital cohort of individuals undergoing gastric bypass surgery, and DMGV levels fell in... (More)

Unbiased, “nontargeted” metabolite profiling techniques hold considerable promise for biomarker and pathway discovery, in spite of the lack of successful applications to human disease. By integrating nontargeted metabolomics, genetics, and detailed human phenotyping, we identified dimethylguanidino valeric acid (DMGV) as an independent biomarker of CT-defined nonalcoholic fatty liver disease (NAFLD) in the offspring cohort of the Framingham Heart Study (FHS) participants. We verified the relationship between DMGV and early hepatic pathology. Specifically, plasma DMGV levels were correlated with biopsy-proven nonalcoholic steatohepatitis (NASH) in a hospital cohort of individuals undergoing gastric bypass surgery, and DMGV levels fell in parallel with improvements in post-procedure cardiometabolic parameters. Further, baseline DMGV levels independently predicted future diabetes up to 12 years before disease onset in 3 distinct human cohorts. Finally, we provide all metabolite peak data consisting of known and unidentified peaks, genetics, and key metabolic parameters as a publicly available resource for investigations in cardiometabolic diseases.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Clinical Investigation
volume
127
issue
12
pages
9 pages
publisher
The American Society for Clinical Investigation
external identifiers
  • pmid:29083323
  • wos:000417141100017
  • scopus:85037121679
ISSN
0021-9738
DOI
10.1172/JCI95995
language
English
LU publication?
yes
id
dad48282-a2f0-4e0b-a471-4d0f293c1b29
date added to LUP
2017-12-18 09:32:16
date last changed
2025-01-07 02:06:42
@article{dad48282-a2f0-4e0b-a471-4d0f293c1b29,
  abstract     = {{<p>Unbiased, “nontargeted” metabolite profiling techniques hold considerable promise for biomarker and pathway discovery, in spite of the lack of successful applications to human disease. By integrating nontargeted metabolomics, genetics, and detailed human phenotyping, we identified dimethylguanidino valeric acid (DMGV) as an independent biomarker of CT-defined nonalcoholic fatty liver disease (NAFLD) in the offspring cohort of the Framingham Heart Study (FHS) participants. We verified the relationship between DMGV and early hepatic pathology. Specifically, plasma DMGV levels were correlated with biopsy-proven nonalcoholic steatohepatitis (NASH) in a hospital cohort of individuals undergoing gastric bypass surgery, and DMGV levels fell in parallel with improvements in post-procedure cardiometabolic parameters. Further, baseline DMGV levels independently predicted future diabetes up to 12 years before disease onset in 3 distinct human cohorts. Finally, we provide all metabolite peak data consisting of known and unidentified peaks, genetics, and key metabolic parameters as a publicly available resource for investigations in cardiometabolic diseases.</p>}},
  author       = {{O’Sullivan, John F. and Morningstar, Jordan E. and Yang, Qiong and Zheng, Baohui and Gao, Yan and Jeanfavre, Sarah and Scott, Justin and Fernandez, Celine and Zheng, Hui and O’Connor, Sean and Cohen, Paul and Vasan, Ramachandran S. and Long, Michelle T. and Wilson, James G. and Melander, Olle and Wang, Thomas J. and Fox, Caroline and Peterson, Randall T. and Clish, Clary B. and Corey, Kathleen E. and Gerszten, Robert E.}},
  issn         = {{0021-9738}},
  language     = {{eng}},
  month        = {{12}},
  number       = {{12}},
  pages        = {{4394--4402}},
  publisher    = {{The American Society for Clinical Investigation}},
  series       = {{Journal of Clinical Investigation}},
  title        = {{Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes}},
  url          = {{http://dx.doi.org/10.1172/JCI95995}},
  doi          = {{10.1172/JCI95995}},
  volume       = {{127}},
  year         = {{2017}},
}